Lv2
182 积分 2021-07-21 加入
Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC
1天前
已完结
Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors
1天前
已完结
Development of an Orally Bioavailable LCK PROTAC Degrader as a Potential Therapeutic Approach to T-Cell Acute Lymphoblastic Leukemia
1天前
已完结
Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer
1天前
已完结
Selective and Orally Bioavailable c-Met PROTACs for the Treatment of c-Met-Addicted Cancer
1天前
已完结
Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition
1天前
已完结
Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader
1天前
已完结
Correction to “Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer”
1天前
已完结
Evaluation of Cereblon-Directing Warheads for the Development of Orally Bioavailable PROTACs
1天前
已完结
Discovery of a Selective and Orally Bioavailable RET Degrader with Effectiveness in Various Mutations
1天前
已完结
皖公网安备34019202002308
